Previous 10 | Next 10 |
MELVILLE, NY / ACCESSWIRE / May 12, 2023 / Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike. BADSC therapy is a novel and proprietary form of regenerative m...
2023-05-08 07:33:29 ET BioRestorative Therapies ( NASDAQ: BRTX ) said New York State's largest health care provider Northwell Health will participate in the company's ongoing phase 2 trial of BRTX-100 to treat chronic lumbar disc disease (cLDD). The trial will evaluate a ...
New York Stat e’s largest health care provider will participate in BRT X ’ s clinical trial Expansive universe of patients and clinical sites from which to recruit high quality subjects L...
MELVILLE, NY., May 04, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Inaug...
BioRestorative Therapies (NASDAQ: BRTX) ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Dis...
-- Clinical data from safety run-in scheduled to be released in second half of 2023 .— MELVILLE, N.Y., April 24, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the ...
(NewsDirect) By Julian Richard, Benzinga BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome with another patent notice of allow...
(NewsDirect) By Julian Richard, Benzinga Successful Autologous Cell-Based Therapies The global CAR-T cell therapy market is growing continuously due to novel clinical and commercial developments in this therapy. As a result, the Global CAR-T cell therapy market is expected to be w...
2023-03-13 07:23:51 ET BioRestorative Therapies ( NASDAQ: BRTX ) signed an agreement with Bruder Consulting & Venture Group for help in seeking FDA approval to expand the clinical application for BRTX-100. The cell therapy BRTX-100 is being evaluated in connection with...
Bruder Consulting & Venture Group engaged to expand BRTX-100 c linical indication p ipeline MELVILLE, N.Y., March 13, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “...
News, Short Squeeze, Breakout and More Instantly...
BioRestorative Therapies Inc Company Name:
BRTX Stock Symbol:
OTCMKTS Market:
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: ...
– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform – – Expanding intellectual property estate expected to help drive ThermoStem ® licensing opportunities – – Substantive di...
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX ...